Clear2Cure is excited to announce a successful funding round that has raised €380,000 to further accelerate our groundbreaking work in the biotech field. As a premier biotech spin-off from Utrecht University, the Netherlands, Clear2Cure is at the forefront of developing Clearbodies®, a novel class of bispecific antibody-derived therapeutics. These innovative therapies are engineered to capture disease targets and direct them to the cell’s natural degradation system, the lysosome, resulting in a rapid and efficient clearance of harmful agents to ensure sustained therapeutic effects. This fresh capital injection exemplifies the growing confidence within the investment community regarding our approach to treating diseases previously deemed undruggable or inadequately addressed by existing therapies.
Our proprietary, modular platform has enabled us to establish a robust preclinical pipeline focused on tackling challenging targets within the infection and immunity space. The funding will be meticulously allocated to accelerate preclinical studies, optimize Clearbodies® and expand our research into severe infections and inflammatory disorders. By bolstering our research and development activities, we aim to transform treatment landscapes for patients who are in critical need of more effective and targeted therapeutic options. We are dedicated to pushing the boundaries of science and innovation, with our mission firmly rooted in revolutionizing treatment protocols for complex diseases. With this new funding, Clear2Cure is well-positioned to harness the potential of emerging biotechnologies and advance its promise of delivering next-generation solutions to patients worldwide.
